2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
pembrolizumab
1282
Specimen Handling
927
Carboplatin
836
Magnetic Resonance Spectroscopy
834
Cyclophosphamide
807
Cisplatin
735
Nivolumab
680
Paclitaxel
635
Radiotherapy
617
Gemcitabine
580
Biopsy
559
Bevacizumab
485
Dexamethasone
444
fludarabine
410
Docetaxel
385
venetoclax
372
Oxaliplatin
367
Capecitabine
361
Fluorouracil
357
atezolizumab
350
durvalumab
340
Rituximab
335
Drug Therapy
333
Radiosurgery
321
Doxorubicin
319
Blood Specimen Collection
317
Standard of Care
311
Pemetrexed
307
Ipilimumab
303
Radiation
287
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled